A municipal worker takes the temperature reading of a worker in Jerusalem (representational image) | Photo: Kobi Wolf | Bloomberg
A municipal worker takes the temperature reading of a worker in Jerusalem (representational image) | Photo: Kobi Wolf | Bloomberg
Text Size:

New Delhi: Researchers from an Israeli hospital claim to have developed a drug that can “cure” Covid-19.

According to doctors at the Ichilov Hospital in Tel Aviv, the preliminary trial results of the drug yielded a 96 per cent positive result on Covid patients.

Called EXO-CD24, it is a targeted drug that was being developed as a cure for cancer for the past few years.

Professor Nadir Arber from Ichilov Hospital’s Integrated Cancer Prevention Center, who has also been part of the drug’s development, said that the hospital had tested the medication on Covid-19 patients in serious and moderate condition.

Out of the 30 patients who were administered EXO-CD24, 29 showed an improvement in two days and were discharged from the hospital within three to five days. One patient took longer to recover.

In light of the positive trial results, the hospital has reached out to Israel health ministry requesting them to extend the trial.


Also read: India’s R value remains steady at 0.92 this week, but many states see a rise in infection rate


Another possible Covid ‘cure’

Apart from the Ichilov Hospital, the Hadassah Medical Center in Jerusalem has also reported a drug that could be a potential cure for Covid-19.

The drug Allocetra, developed by the Israeli immunotherapy company Enlivex Therapeutics, was tested on 16 severe and critical Covid-19 patients.

These patients survived a 28-day phase 2 clinical trial period. The drug attempts to treat the ‘over-response’ of immune system, called a cytokine storm, which is commonly seen in Covid-19 patients requiring critical care.

Out of the 16 patients who were given the treatment, two critical care patients were still in intensive care at the end of the trial. Fourteen other patients recovered successfully and were discharged at the end of the trial.

The average duration of hospitalisation after receiving Allocetra was reported to be 5.3 days.


Also read: Pfizer withdraws application for emergency use of its Covid vaccine in India


 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises.

But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle.

ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here.

Support Our Journalism

VIEW COMMENTS

2 COMMENTS

  1. Let’s get this right. It has a 96% survival rate on a disease that currently in the USA, witch shows the most cases has a 98.5% survival rate?? Seems my odds are better with out taking it.

  2. Hop the Govt and drug regulators take note. Another combination, with a de -worming medicine and some other drug has also shown promising results. We should also carry out testing of the these in our country. It is not known when a mutation, immune to the existing vaccines will emerge. These drugs may be the only hope then, till new vaccines are developed.

Comments are closed.